These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10660944)

  • 1. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
    Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
    Pharmacol Res; 1999 Dec; 40(6):475-82. PubMed ID: 10660944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
    Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
    Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
    Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T
    Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
    Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
    Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
    Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
    Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
    Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
    Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide.
    Hirose H; Maruyama H; Seto Y; Ito K; Fujita T; Dan K; Kanda N; Saruta T; Kato R
    Pharmacology; 1995 Mar; 50(3):175-81. PubMed ID: 7746834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of insulin release in hereditarily diabetic rats by mixed molecules formed of nateglinide and a succinic acid ester.
    Ladriere L; Bjorkling F; Malaisse WJ
    Int J Mol Med; 2000 Jan; 5(1):63-5. PubMed ID: 10601576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
    Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
    Hu S
    Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
    Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
    Eur J Pharmacol; 1998 May; 348(2-3):265-70. PubMed ID: 9652342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
    Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
    Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
    Luo J; Nguyen K; Chen M; Tran T; Hao J; Tian B; Rulifson IC; Zhang Y; Tian L; Zhang Y; Lopez E; Lin DC; Wang Y; Ma Z; Houze J; Guo Z
    Metabolism; 2013 Jan; 62(1):90-9. PubMed ID: 22982177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the methyl esters of pyruvate, succinate and glutamate on the secretory response to meglitinide analogues in rat pancreatic islets.
    Bakkali Nadi A; Zhang TM; Malaisse WJ
    Pharmacol Res; 1996 Mar; 33(3):191-4. PubMed ID: 8880890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
    Kitahara Y; Miura K; Takesue K; Mine T; Wada R; Uchida Y; Ito S; Yagihashi S
    Metabolism; 2002 Nov; 51(11):1452-7. PubMed ID: 12404197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
    Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.